1. Product Overview
2. Research Methodology
3. Impact of COVID-19
on Global Neuroendocrine Tumors Treatment Market
4.
Executive Summary
5. Voice of Customer
6. Global
Neuroendocrine Tumors Treatment Market Outlook
6.1.
Market Size & Forecast
6.1.1.
By Value
6.2.
Market Share & Forecast
6.2.1. By Therapy Type (Chemotherapy,
Immunotherapy, Hormonal Therapy, Surgery, Targeted Therapy, Others)
6.2.2. By Mechanism of
Action (Somatostatin Analogs, Tyrosine Kinase Inhibitor, Peptide receptor
radionuclide, Alfa-interferon, Proton pump inhibitors, Others)
6.2.3. By Drug Type (Everolimus,
Sunitib malate, Lorlatinib, Nivolumab, Bevacizumab, Others)
6.2.4. By
Indication (Gastrointestinal NET, Lung NET, Pancreatic NET, Appendiceal NET,
Others)
6.2.5. By Route of
administration (Oral, Parenteral, Others)
6.2.6. By End User
(Hospitals, Ambulatory Surgical Centers, Oncology Centers, Others (GI centers,
Cardio-thoracic centers, NET centers)
6.2.7. By Company (2020)
6.2.8. By
Region
6.3. Product
Market Map
7. Asia-Pacific
Neuroendocrine Tumors Treatment Market Outlook
7.1.
Market Size & Forecast
7.1.1.
By Value
7.2.
Market Share & Forecast
7.2.1. By Therapy Type
7.2.2. By Mechanism of
Action
7.2.3. By Drug Type
7.2.4. By Indication
7.2.5. By Route of
administration
7.2.6. By End User
7.2.7.
By Country
7.3.
Asia-Pacific: Country Analysis
7.3.1.
China Neuroendocrine Tumors Treatment Market Outlook
7.3.1.1.
Market Size & Forecast
7.3.1.1.1.
By Value
7.3.1.2.
Market Share & Forecast
7.3.1.2.1.
By Therapy Type
7.3.1.2.2.
By Mechanism of action
7.3.1.2.3.
By Drug Type
7.3.1.2.4.
By Indication
7.3.1.2.5.
By Route od administration
7.3.1.2.6.
By End User
7.3.2.
India Neuroendocrine Tumors Treatment Market Outlook
7.3.2.1.
Market Size & Forecast
7.3.2.1.1.
By Value
7.3.2.2.
Market Share & Forecast
7.3.2.2.1.
By Therapy Type
7.3.2.2.2.
By Mechanism of action
7.3.2.2.3.
By Drug Type
7.3.2.2.4.
By Indication
7.3.2.2.5.
By Route od administration
7.3.2.2.6.
By End User
7.3.3.
Japan Neuroendocrine Tumors Treatment Market Outlook
7.3.3.1.
Market Size & Forecast
7.3.3.1.1.
By Value
7.3.3.2.
Market Share & Forecast
7.3.3.2.1.
By Therapy Type
7.3.3.2.2.
By Mechanism of action
7.3.3.2.3.
By Drug Type
7.3.3.2.4.
By Indication
7.3.3.2.5.
By Route od administration
7.3.3.2.6.
By End User
7.3.4.
South Korea Neuroendocrine Tumors Treatment Market
Outlook
7.3.4.1.
Market Size & Forecast
7.3.4.1.1.
By Value
7.3.4.2.
Market Share & Forecast
7.3.4.2.1.
By Therapy Type
7.3.4.2.2.
By Mechanism of action
7.3.4.2.3.
By Drug Type
7.3.4.2.4.
By Indication
7.3.4.2.5.
By Route od administration
7.3.4.2.6.
By End User
7.3.5.
Australia Neuroendocrine Tumors Treatment Market Outlook
7.3.5.1.
Market Size & Forecast
7.3.5.1.1.
By Value
7.3.5.2.
Market Share & Forecast
7.3.5.2.1.
By Therapy Type
7.3.5.2.2.
By Mechanism of action
7.3.5.2.3.
By Drug Type
7.3.5.2.4.
By Indication
7.3.5.2.5.
By Route od administration
7.3.5.2.6.
By End User
8. Europe
Neuroendocrine Tumors Treatment Market Outlook
8.1.
Market Size & Forecast
8.1.1.
By Value
8.2.
Market Share & Forecast
8.2.1. By Therapy Type
8.2.2. By Mechanism of
Action
8.2.3. By Drug Type
8.2.4. By Indication
8.2.5. By Route of
administration
8.2.6.
By End User
8.2.7.
By Country
8.3.
Europe: Country Analysis
8.3.1.
France Neuroendocrine Tumors Treatment Market Outlook
8.3.1.1.
Market Size & Forecast
8.3.1.1.1.
By Value
8.3.1.2.
Market Share & Forecast
8.3.1.2.1.
By Therapy Type
8.3.1.2.2.
By Mechanism of action
8.3.1.2.3.
By Drug Type
8.3.1.2.4.
By Indication
8.3.1.2.5.
By Route od administration
8.3.1.2.6.
By End User
8.3.2.
Germany Neuroendocrine Tumors Treatment Market Outlook
8.3.2.1.
Market Size & Forecast
8.3.2.1.1.
By Value
8.3.2.2.
Market Share & Forecast
8.3.2.2.1.
By Therapy Type
8.3.2.2.2.
By Mechanism of action
8.3.2.2.3.
By Drug Type
8.3.2.2.4.
By Indication
8.3.2.2.5.
By Route od administration
8.3.2.2.6.
By End User
8.3.3.
United Kingdom Neuroendocrine Tumors Treatment Market
Outlook
8.3.3.1.
Market Size & Forecast
8.3.3.1.1.
By Value
8.3.3.2.
Market Share & Forecast
8.3.3.2.1.
By Therapy Type
8.3.3.2.2.
By Mechanism of action
8.3.3.2.3.
By Drug Type
8.3.3.2.4.
By Indication
8.3.3.2.5.
By Route od administration
8.3.3.2.6.
By End User
8.3.4.
Italy Neuroendocrine Tumors Treatment Market Outlook
8.3.4.1.
Market Size & Forecast
8.3.4.1.1.
By Value
8.3.4.2.
Market Share & Forecast
8.3.4.2.1.
By Therapy Type
8.3.4.2.2.
By Mechanism of action
8.3.4.2.3.
By Drug Type
8.3.4.2.4.
By Indication
8.3.4.2.5.
By Route od administration
8.3.4.2.6.
By End User
8.3.5.
Spain Neuroendocrine Tumors Treatment Market Outlook
8.3.5.1.
Market Size & Forecast
8.3.5.1.1.
By Value
8.3.5.2.
Market Share & Forecast
8.3.5.2.1.
By Therapy Type
8.3.5.2.2.
By Mechanism of action
8.3.5.2.3.
By Drug Type
8.3.5.2.4.
By Indication
8.3.5.2.5.
By Route od administration
8.3.5.2.6.
By End User
9. North America
Neuroendocrine Tumors Treatment Market Outlook
9.1.
Market Size & Forecast
9.1.1.
By Value
9.2.
Market Share & Forecast
9.2.1. By Therapy Type
9.2.2. By Mechanism of
Action
9.2.3. By Drug Type
9.2.4. By Indication
9.2.5. By Route of
administration
9.2.6.
By End User
9.2.7.
By Country
9.3.
North America: Country Analysis
9.3.1.
United States Neuroendocrine Tumors Treatment Market
Outlook
9.3.1.1.
Market Size & Forecast
9.3.1.1.1.
By Value
9.3.1.2.
Market Share & Forecast
9.3.1.2.1.
By Therapy Type
9.3.1.2.2.
By Mechanism of action
9.3.1.2.3.
By Drug Type
9.3.1.2.4.
By Indication
9.3.1.2.5.
By Route od administration
9.3.1.2.6.
By End User
9.3.2.
Mexico Neuroendocrine Tumors Treatment Market Outlook
9.3.2.1.
Market Size & Forecast
9.3.2.1.1.
By Value
9.3.2.2.
Market Share & Forecast
9.3.2.2.1.
By Therapy Type
9.3.2.2.2.
By Mechanism of action
9.3.2.2.3.
By Drug Type
9.3.2.2.4.
By Indication
9.3.2.2.5.
By Route od administration
9.3.2.2.6.
By End User
9.3.3.
Canada Neuroendocrine Tumors Treatment Market Outlook
9.3.3.1.
Market Size & Forecast
9.3.3.1.1.
By Value
9.3.3.2.
Market Share & Forecast
9.3.3.2.1.
By Therapy Type
9.3.3.2.2.
By Mechanism of action
9.3.3.2.3.
By Drug Type
9.3.3.2.4.
By Indication
9.3.3.2.5.
By Route od administration
9.3.3.2.6.
By End User
10. South America
Neuroendocrine Tumors Treatment Market Outlook
10.1.
Market Size & Forecast
10.1.1.
By Value
10.2.
Market Share & Forecast
10.2.1. By Therapy Type
10.2.2. By Mechanism of
Action
10.2.3. By Drug Type
10.2.4. By Indication
10.2.5. By Route of
administration
10.2.6.
By End User
10.2.7.
By Country
10.3.
South America: Country Analysis
10.3.1.
Brazil Neuroendocrine Tumors Treatment Market Outlook
10.3.1.1.
Market Size & Forecast
10.3.1.1.1.
By Value
10.3.1.2.
Market Share & Forecast
10.3.1.2.1.
By Therapy Type
10.3.1.2.2.
By Mechanism of action
10.3.1.2.3.
By Drug Type
10.3.1.2.4.
By Indication
10.3.1.2.5.
By Route od administration
10.3.1.2.6.
By End User
10.3.2.
Argentina Neuroendocrine Tumors Treatment Market Outlook
10.3.2.1.
Market Size & Forecast
10.3.2.1.1.
By Value
10.3.2.2.
Market Share & Forecast
10.3.2.2.1.
By Therapy Type
10.3.2.2.2.
By Mechanism of action
10.3.2.2.3.
By Drug Type
10.3.2.2.4.
By Indication
10.3.2.2.5.
By Route od administration
10.3.2.2.6.
By End User
10.3.3.
Colombia Neuroendocrine Tumors Treatment Market Outlook
10.3.3.1.
Market Size & Forecast
10.3.3.1.1.
By Value
10.3.3.2.
Market Share & Forecast
10.3.3.2.1.
By Therapy Type
10.3.3.2.2.
By Mechanism of action
10.3.3.2.3.
By Drug Type
10.3.3.2.4.
By Indication
10.3.3.2.5.
By Route od administration
10.3.3.2.6.
By End User
11. Middle East and
Africa Neuroendocrine Tumors Treatment Market Outlook
11.1.
Market Size & Forecast
11.1.1.
By Value
11.2.
Market Share & Forecast
11.2.1. By Therapy Type
11.2.2. By Mechanism of
Action
11.2.3. By Drug Type
11.2.4. By Indication
11.2.5. By Route of
administration
11.2.6.
By End User
11.2.7.
By Country
11.3.
MEA: Country Analysis
11.3.1.
South Africa Neuroendocrine Tumors Treatment Market
Outlook
11.3.1.1.
Market Size & Forecast
11.3.1.1.1.
By Value
11.3.1.2.
Market Share & Forecast
11.3.1.2.1.
By Therapy Type
11.3.1.2.2.
By Mechanism of action
11.3.1.2.3.
By Drug Type
11.3.1.2.4.
By Indication
11.3.1.2.5.
By Route od administration
11.3.1.2.6.
By End User
11.3.2.
Saudi Arabia Neuroendocrine Tumors Treatment Market
Outlook
11.3.2.1.
Market Size & Forecast
11.3.2.1.1.
By Value
11.3.2.2.
Market Share & Forecast
11.3.2.2.1.
By Therapy Type
11.3.2.2.2.
By Mechanism of action
11.3.2.2.3.
By Drug Type
11.3.2.2.4.
By Indication
11.3.2.2.5.
By Route od administration
11.3.2.2.6.
By End User
11.3.3.
UAE Neuroendocrine Tumors Treatment Market Outlook
11.3.3.1.
Market Size & Forecast
11.3.3.1.1.
By Value
11.3.3.2.
Market Share & Forecast
11.3.3.2.1.
By Therapy Type
11.3.3.2.2.
By Mechanism of action
11.3.3.2.3.
By Drug Type
11.3.3.2.4.
By Indication
11.3.3.2.5.
By Route od administration
11.3.3.2.6.
By End User
12. Market Dynamics
12.1.
Drivers
12.2.
Challenges
13. Market Trends &
Developments
14. Competitive
Landscape
14.1.
Competition Outlook
14.2.
Players Profiled
14.2.1.
F. Hoffmann-La Roche
Ltd.
14.2.2.
Bristol-Myers Squibb
AB
14.2.3.
Eli Lilly &
Company
14.2.4.
Novartis AG
14.2.5.
Pfizer Inc.
14.2.6.
Amgen, Inc.
14.2.7.
Exelixis Inc.
14.2.8.
Teva Pharmaceuticals
Ltd.
14.2.9.
Callisto
Pharmaceuticals Pvt. Ltd.
14.2.10.
Boehringer Ingelheim
GmbH
14.2.11.
Dauntless Pharmaceuticals
Inc.
14.2.12.
Hutchison MediPharma
Limited
14.2.13.
AVEO
Pharmaceuticals, Inc.
14.2.14.
Aegis Therapeutics
LLC
14.2.15.
Progenics
Pharmaceuticals, Inc.
15.
Strategic Recommendations
16.
About Us & Disclaimer
In case you don’t find what you are looking for, please get in touch with our custom research team at sales@techsciresearch.com